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Table 1. Survival outcomes following the HKLC and BCLC staging systems in a population of European hepatocellular carcinoma patients.
Score Median OS (95% CI) p value
(Log-rank)
Survival probability
 Years                          Survival probability % ± Sd
HKLC stage
I (n = 135) 54.8 (39.6-80.4)
<0.0001
5 0.495 ± 0.057
IIa (n = 40) 24.3 (18.7-49.6) 5 0.255 ± 0.098
IIb (n = 155) 26.4 (22.7-32.4) 5 0.142 ± 0.038
IIIa (n = 40) 14.6 (11.2-17.2) 3 0.041 ± 0.040
IIIb (n = 172) 9.6 (8.2-11.7) 3 0.068 ± 0.023
IVa (n = 44) 9.3 (6.1-13.5) 1 0.361 ± 0.073
IVb (n = 19) 4.0 (2.4-5.1) 1 0
Va (n = 9) 8.1 (4.1-10.2) 5 0
Vb (n = 51) 3.0 (2.0-4.1) 1 0.030 ± 0.029
BCLC stage
A (n = 177) 45.7 (37.5-68.0)
<0.0001
5 0.449 ± 0.049
B (n = 207) 21.3 (18.3-25.2) 3 0.264 ± 0.036
C (n = 236) 8.3 (7.1-10.1) 2 0.124 ± 0.250
D (n = 45) 2.7 (2.0-4.1) 1 0.056 ± 0.038
Survival probability estimate was reported at t = 5 years for stages I, IIa, IIb, and Va; t = 3 years for stages III and IIIb; and t = 1 year for stages IVa, IVb, and Vb.
CI, conﬁdence interval.
Transient increase in urine protein excretion during treatment with
terlipressin and albumin for type-1 hepatorenal syndrome
To the Editor:
We recently had a patient admitted to our unit with cirrhosis and
type-1 hepatorenal syndrome (HRS) who developed marked pro-
teinuria during treatment with terlipressin and albumin. This led
us to investigate whether pharmacological treatment of type-1
HRS could be associated with an increase in urine protein excre-
tion. The effects of terlipressin and albumin on kidney function in
patients with type-1 HRS have been investigated extensively
[1,2], but to our knowledge there is no information on the poten-
tial effects of treatment on urine protein. We evaluated a series of
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29 patients with type-1 HRS, treated at our institution. Patients
were selected from a database of 75 patients with type-1 HRS,
treated in our unit in the last 15 years. Clinical and laboratory
data from all patients were recorded prospectively in this data-
base at the time of treatment. For this analysis we selected 29
patients who had urine protein measurements available before
treatment and at two time points during treatment. There were
no signiﬁcant differences regarding baseline liver and kidney
function tests and the percentage of response to treatment
between these 29 patients and the remaining 46 patients
included in the database. Urine analyses were performed before
treatment, at days 3–4, and at the end of treatment. The
individual values of urine protein excretion in all patients evalu-
ated are shown in Fig. 1 (left panel). Treatment with terlipressin
and albumin was associated with a statistically signiﬁcant
increase in urine protein excretion that returned towards base-
line values at the end of treatment (239 ± 151, 675 ± 961, and
380 ± 459 mg/24 h at baseline, days 3–4, and at the end of treat-
ment, respectively; mean ± standard deviation, p = 0.001). Inter-
estingly, in 4 of the 29 patients (14%) urine protein excretion
increased above 1 g/day during treatment. To assess whether
the magnitude of the increase in urine protein excretion was
related to the response to treatment, we categorized patients into
two groups according to urine protein excretion during treatment
with terlipressin and albumin (patients with urine protein
P500 mg/24 h vs. patients with urine protein <500 mg/24 h).
There were no signiﬁcant differences between the two subsets
of patients regarding baseline liver, kidney and circulatory func-
tion, dose of terlipressin used or length of therapy. In the overall
series, the mean duration of therapy was 7 ± 4 days (7 ± 3 and
8 ± 45 days in patients with urine protein P500 mg/24 h vs.
patients with urine protein <500 mg/24 h, respectively; p = 0.7).
Overall, 18 out of the 29 patients (62%) had complete response
to treatment (serum creatinine <1.5 mg/dl at the end of treat-
ment). The development of proteinuria was not related to an
impaired response to treatment. In fact, three out of the 7
patients (43%) with urine protein excretion P500 mg/24 h had
a complete response to treatment compared to 15 out of the 22
patients (68%) with urine protein excretion <500 mg/24 h
(p = 0.37). Moreover, 3 of the 4 patients with excretion greater
than 1 g/day had a complete response to therapy. Urine protein
excretion in responders to treatment with terlipressin and albumin
was 268 ± 157, 756 ± 1178, and 436 ± 571 mg/24 h (at baseline,
p = n.s.p = 0.001
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Fig. 1. Evolution of urine protein excretion in patients with type-1 hepatorenal syndrome. Evolution of urine protein excretion in patients with type-1 hepatorenal
syndrome treated with terlipressin and albumin (left panel) and in patients treated with albumin alone (right panel).
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494 Journal of Hepatology 2days 3–4, and end of treatment, respectively) compared to 191 ± 133,
543 ± 439, and 287 ± 138 mg/24 h in non-responders (p = n.s.).
To assess to what extent the increase in urine protein excre-
tion was related to treatment with terlipressin plus albumin or
could be related to the administration of intravenous albumin
alone we also investigated a historical control group of 12
patients with type-1 HRS, associated with bacterial infections
that were treated with albumin alone, included in a previous
study [3]. In this series of patients urianalysis was performed
before treatment and at day 3. In patients with type-1 HRS, trea-
ted with albumin alone, there was no signiﬁcant increase in urine
protein excretion during treatment (108 ± 67 vs. 143 ± 118 at
baseline and at day 3, respectively; p = n.s.). The individual values
of urine protein excretion in patients treated with albumin alone
are shown in Fig. 1 (right panel).
The pathogenic mechanisms responsible for the increase in
urine protein during treatment with terlipressin and albumin
were not assessed in this study. This effect could be related to
the increased renal perfusion pressure caused by terlipressin
administration. It is also possible that terlipressin treatment
may uncover some preexisting parenchymal nephropathy [4].
In conclusion, regardless of the mechanism involved, our results
indicate that treatment with terlipressin and albumin is
associated with a transient increase in urine protein excretion
that is signiﬁcant in some patients. Based on our ﬁndings, the
development of an increase in urine protein excretion during
treatment of type-1 HRS should not modify the diagnosis and
treatment of kidney failure. This information may be clinically
useful for clinicians, caring for patients with acute complications
of cirrhosis.Conﬂict of interest
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Deﬁciency of periostin protects mice against
methionine-choline-deﬁcient diet-induced
non-alcoholic steatohepatitis
To the Editor:
Non-alcoholic fatty liver disease (NAFLD), themost common cause
of chronic liver diseaseworldwide, encompasses a spectrumof dis-
eases ranging from simple steatosis to non-alcoholic steatohepati-
tis (NASH) [1,2]. Periostin (encoded by POSTN), a matricellular
protein, plays an important role in various inﬂammatorydisorders,
such as airway inﬂammation, skin inﬂammation, atherosclerosis
and ﬁbrosis [3,4], and actively contributes to tumour metastasis
[5–7]. However, until the recent publication by Lu et al. [8], there
wasnoknown linkbetweenperiostin andNAFLD. Lu et al. [8] found
that hepatic periostin expression is dramatically increased in high-
fat diet (HFD)-fed mice, ob/ob mice and db/db mice, as well as in
NAFLD patients. Lu et al. [8] further demonstrated that periostin
is a crucial contributing factor in aberrant hepatic triglyceride
(TG) accumulation and in the pathogenesis of obesity-induced
hepatosteatosis. However, the role of periostin in the pathogenesis
of NASH remains unknown [9]. As an aggressive form of fatty liver
disease, NASH is characterized by histopathological features, such
as steatosis, inﬂammation and ﬁbrosis, and is often accompanied
by the metabolic syndrome, such as diabetes, insulin resistance
and obesity. Moreover, some individuals with NASH eventually
advance to liver cirrhosis and/or hepatocellular carcinoma,
whereas hepatic steatosis usually has no serious clinical
consequences [2,9]. Because genetically induced rodent obesity
or HFD-induced hepatic steatosis does not progress to steatohepa-
titis, we now present data to determine the role of periostin
in the development of methionine-choline-deﬁcient (MCD) diet-
induced NASH in mice.
To reveal the role of periostin in the development of NASH, we
fed two groups of C57BL/6J mice with either regular chow or the
MCD diet for 4 weeks. MCD diet-fed mice developed hepatic
steatosis whereas chow-fed mice did not develop steatosis. The
MCD diet also resulted in inﬂammation and ﬁbrosis in mouse
liver tissue (data not shown). We found that periostin was
markedly upregulated and mainly distributed around steatotic
hepatocytes in the MCD diet-fed mice by immunohistochemical
staining (Fig. 1A). Western blotting and qRT-PCR analyses further
demonstrated that the protein and mRNA levels of liver periostin
were dramatically increased in MCD diet-fed mice compared
with control mice (Fig. 1B and C). Moreover, we found that mice
fed the MCD diet for 8 weeks, also developed NASH and showed
phenotypes of steatosis, inﬂammation and ﬁbrosis. The protein
and mRNA levels of liver periostin in mice fed the MCD diet for
8 weeks were also signiﬁcantly upregulated (data not shown).
These data suggest that periostin may be involved in the
development of MCD diet-induced NASH.
To determine whether periostin deﬁciency abrogates the
progression of NASH, we used a periostin-deﬁcient mouse model.
Heterozygous B6;129-Postntm1Jmol/J (Postn+/) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, Maine, USA).
Periostin-deﬁcient and periostin wild type mice were generated
from crossing Postn+/ with Postn+/ mice. After feeding the
MCD diet for 4 weeks, periostin-deﬁcient mice exhibited signiﬁ-
cantly less TGs in their livers compared to the wild type group
(Fig. 1D). The serum level of alanine aminotransferase was mark-
edly decreased in Postn/ mice compared to wild type mice
(Fig. 1E), indicating that the MCD diet produced a more severe
liver injury in wild type mice than in Postn/ mice. Moreover,
MCD diet feeding resulted in an increased collagen deposition
in wild type mice, as shown by Sirius red staining; however, col-
lagen deposition was signiﬁcantly lower in Postn/ mice than in
wild type mice after being on the MCD diet (Fig. 1F and G), sug-
gesting that Postn/ mice exhibited signiﬁcantly less histological
ﬁbrosis compared to the wild type group. We also found that
mRNA levels of the inﬂammatory and ﬁbrotic factors IL-6, TGF-b1,
and a-SMA were markedly increased in livers of MCD diet-fed
wild type mice compared to the chow diet-fed wild type controls;
however, the mRNA levels of IL-6, TGF-b1, and a-SMAwere signif-
icantly lower in the liver tissue of Postn/ mice than in wild type
mice after being on the MCD diet for 4 weeks (Fig. 1H). Therefore,
these data suggest that a deﬁciency in periostin abrogates the
development of MCD diet-induced NASH in mice.
In conclusion, our work demonstrates that periostin is highly
expressed in MCD diet-induced NASH and that periostin knock-
out mice show a markedly lower degree of steatosis, inﬂamma-
tion and ﬁbrosis compared with wild type mice after being fed
the MCD diet. As previously mentioned, hepatic periostin levels
are signiﬁcantly upregulated in monogenic-induced obese mice
and HFD-fed mice, as well as in patients with fatty liver disease
[8]. Therefore, these data demonstrate that periostin is a potential
diagnostic marker and therapeutic target for hepatosteatosis,
NASH and even other liver diseases.
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